The Novel A-Flux Coronary Sinus Reducer Normalizes Coronary Microvascular Function in a Persistently Symptomatic Patient
Coronary microvascular dysfunction (CMD) contributes to persistent angina/anginal equivalent symptoms and is associated with adverse outcomes. Coronary sinus reduction (CSR) is a device-based therapy with the potential to improve outcomes by reducing symptom burden and improving coronary flow reserve. A patient with CMD underwent CSR with the next-generation A-Flux device.
Authors
- Giovanni Occhipinti (ORCID: https://orcid.org/0000-0003-0157-7242)
- Manel Sabaté (ORCID: https://orcid.org/0000-0002-2316-3705)
- Eduardo Flores‐Umanzor (ORCID: https://orcid.org/0000-0002-6428-241X)
- Ander Regueiro (ORCID: https://orcid.org/0000-0001-5201-447X)
- Omar Abdul‐Jawad Altisent (ORCID: https://orcid.org/0000-0002-8884-0172)
- Salvatore Brugaletta (ORCID: https://orcid.org/0000-0001-5845-1435)
- Francesco Giannini (ORCID: https://orcid.org/0000-0002-3391-9860)
- Rishi Puri (ORCID: https://orcid.org/0000-0001-8849-7426)
- Anthony Salazar-Rodríguez
Institutions
- Cleveland Clinic (US)
- Hospital Clínic de Barcelona (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1016/j.jaccas.2024.102962
- Primary Topic
- Cardiac Imaging and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00